SILO (Silo Pharma, Inc. Common Stock) Stock Analysis - News
Silo Pharma, Inc. Common Stock (SILO) is a publicly traded Healthcare sector company. As of May 21, 2026, SILO trades at $0.37 with a market cap of $6.31M and a P/E ratio of -0.76. SILO moved -0.13% today. Year to date, SILO is +5.20%; over the trailing twelve months it is -23.78%. Its 52-week range spans $0.22 to $3.37. Rallies surfaces SILO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in SILO news today?
Silo Pharma Seeks Patent for Ibogaine TBI Therapy in $6B Market: Silo Pharma filed a provisional USPTO patent for ibogaine-based compositions and methods targeting traumatic brain injury and related neuropsychiatric conditions. The global TBI therapeutics market is projected to reach $6.0 billion by 2032, and early data show ibogaine protocols may increase cortical thickness and reduce depression and anxiety.
Weisblum Eric bought 2.50K (~$1.02K) on Dec 15, 2025.
Weisblum Eric bought 2.50K (~$1.05K) on Dec 15, 2025.
Weisblum Eric bought 1.00K (~$365) on Nov 21, 2025.
SILO Analyst Consensus
SILO analyst coverage data. Average price target: $0.00.
Common questions about SILO
What changed in SILO news today?
Silo Pharma Seeks Patent for Ibogaine TBI Therapy in $6B Market: Silo Pharma filed a provisional USPTO patent for ibogaine-based compositions and methods targeting traumatic brain injury and related neuropsychiatric conditions. The global TBI therapeutics market is projected to reach $6.0 billion by 2032, and early data show ibogaine protocols may increase cortical thickness and reduce depression and anxiety.
Does Rallies summarize SILO news?
Yes. Rallies summarizes SILO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is SILO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SILO. It does not provide personalized investment advice.
